Active	Status	Sponsor type	Region	Phase	Filter
6 Active 11 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Daud, Adil
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers	Active, not recruiting	2	77	Europe, Canada, US	SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin	Seagen Inc., Merck Sharp & Dohme LLC	Melanoma, Carcinoma, Non-Small- Cell Lung	01/24	10/25
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection	Terminated	2	7	US	Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay	Washington University School of Medicine, Genentech, Inc.	Stage II Melanoma	11/23	11/23
OMNIA-1, NCT05578872 / 2021-006711-29: A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma ().	Completed	1/2	29	Europe, US	ANV419, Pembrolizumab, Ipilimumab	Anaveon AG, Anaveon AG	Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma	08/24	08/24
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors	Recruiting	1	275	Europe, Canada, US	PF-08046049	Seagen Inc.	Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma	11/26	11/27
NCT05695898: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy	Active, not recruiting	1	6	US	XmAb22841, CTLA-4 X LAG3, Bavunalimab, XmAb23104, PD1 X ICOS, XmAb104	University of California, San Francisco, Xencor, Inc.	Metastatic Melanoma, Advanced Melanoma	12/25	12/25
NCT05105100: Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma	Recruiting	N/A	25	US	Biopsy, Excisional Biopsy, Biospecimen Collection, Specimen Collection	University of California, San Francisco, Merck Sharp & Dohme LLC	Melanoma, Advanced Melanoma	08/26	08/26
Daud, Adil I
No trials found